Drug Type CAR-T |
Synonyms Anti-CD19-chimeric-antigen-receptor-transduced T cells(National Cancer Institute) |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adult Lymphoblastic Lymphoma | Phase 2 | United States | 03 Sep 2024 | |
| B-Cell Lymphoma | Phase 2 | United States | 03 Sep 2024 | |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 2 | United States | 03 Sep 2024 | |
| Chronic lymphocytic leukaemia refractory | Phase 2 | United States | 03 Sep 2024 | |
| Lymphoblastic Leukemia, Acute, With Lymphomatous Features | Phase 2 | United States | 03 Sep 2024 | |
| Recurrent Adult Acute Lymphoblastic Leukemia | Phase 2 | United States | 03 Sep 2024 | |
| Refractory acute lymphoid leukemia | Phase 2 | United States | 03 Sep 2024 | |
| Richter's syndrome | Phase 2 | United States | 03 Sep 2024 | |
| Small Lymphocytic Lymphoma | Phase 2 | United States | 03 Sep 2024 | |
| Follicular Lymphoma | Phase 2 | United States | 17 Feb 2009 |
Phase 1/2 | 43 | (0.5x10^7 Cells/kg) | hecrojcffs = giqhxhklhs dpxtguczxm (pxpwaulebj, nntnbcphpe - sfqhkhkkcr) View more | - | 21 Mar 2019 | ||
(2.5x10^6 Cells/kg) | hecrojcffs = lbcvootwbm dpxtguczxm (pxpwaulebj, ppdmabjwhx - nnfaykkniw) View more |





